

Eur Arch Psychiatry Clin Neurosci (2012) 262:657–666  
DOI 10.1007/s00406-012-0301-3

## ORIGINAL PAPER

# Phosphoproteomic differences in major depressive disorder postmortem brains indicate effects on synaptic function

Daniel Martins-de-Souza · Paul C. Guest ·  
Natacha Vanattou-Saifoudine · Hassan Rahmoune ·  
Sabine Bahn

Received: 16 November 2011 / Accepted: 31 January 2012 / Published online: 21 February 2012  
© The Author(s) 2012. This article is published with open access at [Springerlink.com](http://Springerlink.com)

**Abstract** There is still a lack in the molecular comprehension of major depressive disorder (MDD) although this condition affects approximately 10% of the world population. Protein phosphorylation is a posttranslational modification that regulates approximately one-third of the human proteins involved in a range of cellular and biological processes such as cellular signaling. Whereas phosphoproteome studies have been carried out extensively in cancer research, few such investigations have been carried out in studies of psychiatric disorders. Here, we present a comparative phosphoproteome analysis of *post-mortem* dorsolateral prefrontal cortex tissues from 24 MDD patients and 12 control donors. Tissue extracts were analyzed using liquid chromatography mass spectrometry in a data-independent manner (LC-MS<sup>E</sup>). Our analyses resulted

in the identification of 5,195 phosphopeptides, corresponding to 802 non-redundant proteins. Ninety of these proteins showed differential levels of phosphorylation in tissues from MDD subjects compared to controls, being 20 differentially phosphorylated in at least 2 peptides. The majority of these phosphorylated proteins were associated with synaptic transmission and cellular architecture not only pointing out potential biomarker candidates but mainly shedding light to the comprehension of MDD pathobiology.

**Keywords** Major depression · Phosphoproteome · Proteome · Phosphorylation · Mass spectrometry · Postmortem

## Introduction

Major depressive disorder (MDD) is characterized by feelings of low mood and self-esteem and by loss of interest or pleasure in activities [12]. The consequences of MDD include negative effects on work and social relationships and associated comorbidities such as substance abuse and anxiety, which results in an enormous financial burden on healthcare services. The combination of direct costs, mortality costs arising from depression-related suicides and costs associated with effects on the workplace were estimated to be over 80 billion dollars in the United States alone in the year 2000 [14]. MDD is now thought to be a leading cause of disability worldwide and has been hypothesized to be the most incident disease of the twenty-first century [12]. Despite the fact that a number of molecular and image-based studies have been performed, an understanding of the underlying pathophysiology is still lacking, and there are still no robust empirical means of increasing our ability to diagnose such conditions accurately.

**Electronic supplementary material** The online version of this article (doi:[10.1007/s00406-012-0301-3](https://doi.org/10.1007/s00406-012-0301-3)) contains supplementary material, which is available to authorized users.

D. Martins-de-Souza (✉) · P. C. Guest ·  
N. Vanattou-Saifoudine · H. Rahmoune · S. Bahn  
Department of Chemical Engineering and Biotechnology,  
University of Cambridge, Tennis Court Road, Cambridge,  
Cambridgeshire CB2 1QT, UK  
e-mail: [danms90@gmail.com](mailto:danms90@gmail.com)

D. Martins-de-Souza  
Max Planck Institute of Psychiatry, Proteomics and Biomarkers,  
Munich, Germany

S. Bahn  
Department of Neuroscience, Erasmus Medical Centre,  
Rotterdam, The Netherlands

The Human Proteome Organization (HUPO) emerged from the Human Genome Project as a means of understanding gene and protein functions that may lead to the understanding of diseases such as MDD and to the identification of diagnostic/prognostic biomarkers [44]. The human genome is now known to contain approximately 35,000 genes [26, 58], although the number of proteins is anticipated to be at least one order of the magnitude greater. One reason for this high number is due to the fact that proteins can undergo posttranslational modifications such as phosphorylation [48], which can give rise to multiple forms of the same gene product.

Recent advances have been made in the development and application of large-scale molecular profiling techniques such as transcriptomics [43] and proteomics [4, 38, 39] in studies of biological tissues from MDD patients. However, there have only been a few studies on differential patterns of protein phosphorylation in MDD [38]. Phosphorylation controls a diverse range of cellular processes such as cell signaling via switching mechanism of the kinase-mediated addition of a high energy phosphate group to a serine, threonine or tyrosine residue on a protein. The large-scale analyses and quantification of phosphoproteins and/or phosphopeptides using mass spectrometry are known as phosphoproteomics and have been employed mostly in studies of cancer [2, 10] and neurodegenerative disorders studies [9, 15]. For instance, the hyperphosphorylation of TAU is one of the central mediators of Alzheimer's disease (AD) pathogenesis. Studies of TAU phosphorylation have proven to be an effective example of how to discover molecular mechanisms and signaling pathways involved in pathogenic processes in the brain. Phosphoproteomics offer us the possibility of investigating in a large-scale manner the functional role of proteins, which is a subject mostly neglected in large-scale proteome studies. Investigation of changes in the phosphorylation states of proteins, which are independent of changes in their total expression, can provide insights about molecular signaling and mechanisms such as neuroplasticity and synaptic transmission.

Here, we have carried out a differential phosphoproteomic analysis of postmortem dorsolateral prefrontal cortex (DLPFC) tissue from MDD patients ( $n = 24$ ) compared to matched controls ( $n = 12$ ) using liquid chromatography mass spectrometry in a data-independent mode (LC-MS<sup>E</sup>). Our interest in the DLPFC arises from the important role that this brain structure plays in MDD pathogenesis [24]. It was of particular importance to determine whether differential phosphorylation is involved in the pathogenesis of MDD and whether such molecules might be used as potential biomarker candidates [32] as a means of developing novel molecular biomarker tests to improve diagnosis and for use as surrogate biomarkers in drug discovery studies.

## Methods and materials

### Brain tissue samples

*Postmortem* DLPFC tissues (Brodmann area 9) from 24 MDD patients and 12 matched control subjects were obtained from the Stanley Medical Research Institute brain collection (Bethesda, MD, USA) (Table 1 and Supplementary Material 1). Consent was obtained by questionnaire-based telephone interview and signed by the interviewer and a witness. The Institutional Review Board at the Uniformed Services University of Health Sciences determined that the procedure was exempt from federal and state regulations governing human research, since specimens were obtained from cadavers and anonymized with respect to personal information.

### Sample preparation

Brain tissue samples (20 mg) were homogenized individually in 100  $\mu$ L of 7 M urea, 2 M thiourea, 4% CHAPS, 2% ASB-14 and 70 mM DTT [40] using the Sample Grinding Kit (GE Healthcare; Little Chalfont, Bucks, UK). Samples were centrifuged for 10 min at 16,000 $\times$ g. The supernatants were collected and protein concentrations determined using the Bradford dye-binding assay (Sigma; Poole, Dorset, UK).

### Shotgun LC-MS<sup>E</sup> proteomics workflow

The following workflow was established previously [37]. Protein samples (15  $\mu$ g) were subjected to sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE) for pre-fractionation to enhance phosphoproteome coverage. Protein bands were visualized using Coomassie blue staining, and each lane containing stained protein bands was sliced to produce 3 horizontal sections. Gel sections were subjected to trypsin digestion in situ and resulting peptide mixtures were lyophilized. The peptides were suspended in 0.1% formic acid and injected (0.5  $\mu$ g) in duplicate into a nano Ultra Performance Liquid Chromatography instrument containing a BEH-130 C18 column (75  $\mu$ m  $\times$  200 mm) at a flow rate of 0.3  $\mu$ L/min connected online to a Q-TOF Premier Mass Spectrometer (Waters Corporation; Manchester, UK). Eluted peptides were measured in MS<sup>E</sup> mode (data-independent analysis) using the ion accounting algorithm [28] for data processing. Analysis of the resulting chromatograms/mass spectra and database searching were performed using the ProteinLynx Global Server (PLGS) v.2.4 (Waters Corp.). Quantitative and statistical analyses were performed using the Rosetta Elucidator<sup>®</sup> system v.3.3.0.1.SP3.19 (Rosetta Inpharmatics; Seattle, WA, USA).

## Statistical analyses

Wilcoxon signed-rank test was used to determine significant differences between the groups under comparison ( $p < 0.05$ ) in case data are not normally distributed. False discovery rate (FDR) was calculated according to Benjamini and Hochberg [5]. No adjustments were made for multiple comparisons as previously supported [53]. This approach is to avoid the exclusion of possible true positives since proteomic data are not necessarily random but can be physiologically interdependent observations, even though a Q-value threshold of approximately 0.4 and a fold change cut off of 10% have been established.

Considering that MDD and controls groups are matched for demographic variables (Table 1), results here are unlike to have suffered influence of gender, age, alcohol abuse, smoking, postmortem interval and refrigeration interval. By using principal component analysis (PCA), we could observe that potential interferences of medication are also unlikely (Supplementary Material 1).

## Phosphoproteome analyses

Potential phosphorylated molecules were identified automatically by PLGS based on the experimentally determined loss of a 80 Da PO3<sup>−</sup> ion from peptides containing one or more phosphorylation consensus sequences featuring serine, threonine or tyrosine residues. Quantification was performed using the Elucidator<sup>®</sup> system.

## Western blot validation

Brain tissue samples were prepared as described above. Samples were arranged in randomized order such that each of the two diagnostic groups (Controls vs. MDD) was represented on each gel. For each sample, 40 µg of total protein was electrophoresed using pre-cast Novex 10–20% Tricine polyacrylamide gels (Invitrogen; Paisley, UK) at

150 V for about 60 min, followed by semidry electrophoretic transfer to Immobilon-FL polyvinylidene fluoride (PVDF) membranes (Millipore; Watford, UK). The membranes were incubated in a 1:1 mixture of Odyssey blocking buffer (Li-COR Biosciences; Cambridge, UK). Membranes were then incubated overnight at 4°C with anti-Dynamin 1 (phospho S774) antibody (ab55324) at 1/500 dilutions (Abcam; Cambridge, UK). The membranes were washed in Tris-buffered saline (TBS) containing 0.1% Tween-20 for 1 h at room temperature ( $4 \times 20$  min) and then incubated for 1 h at room temperature with the appropriate IR-dye-conjugated secondary antibodies (1:7,500 for secondary rabbit antibody Li-COR Biosciences) in blocking buffer. Immunoreactive protein bands were visualized using the Odyssey Infra-red imaging system (Li-COR Biosciences) and the integrated intensities (II) of the bands measured. Values which lay outside the mean by more than twice the standard deviation were excluded from the analysis.

## Biological classification

Differentially phosphorylated proteins in MDD DLPFC were classified according to their biological pathways and subcellular localization using the Human Protein Reference Database (<http://www.hprd.org>). For interpreting functional significance of differentially phosphorylated proteins, the associated SwissProt accession identification codes for each phosphoprotein were uploaded into the Ingenuity Pathways Knowledge Base (IPKB) (<http://www.ingenuity.com>), and these were analyzed to identify potential interactions between these proteins and other proteins in the IPKB and for determining the most significant biological, disease and canonical pathways associated with these proteins (significance determined using Fisher's exact test).

## Results

Using our shotgun LC-MS<sup>E</sup> approach, we could identify 5,195 phosphopeptides in all the 36 analyzed samples corresponding to 802 distinct proteins. Comparing MDD patient samples to controls, significant differences in phosphorylation levels ( $p < 0.05$ —Wilcoxon signed-rank test) were observed for 116 phosphopeptides, corresponding to 90 distinct proteins (Table 2). Ten of these proteins (11.1%—Table 2 in black) were found with differences in protein expression, which impairs the confirmation of their differential phosphorylation. Fifty-three proteins (58.9%) presented phosphorylation differences in one phosphorylation site in a single peptide, while 17 proteins (18.9%) presented phosphorylation differences in at least 2

**Table 1** Demographic information for the samples used in the study (mean  $\pm$  SD)

	Control	MDD	Significance <i>t</i> test ( <i>p</i> )
Sample size	12	24	
Age	47 $\pm$ 12	42 $\pm$ 11	0.38
Postmortem interval	25.3 $\pm$ 10.6	29.7 $\pm$ 12.4	0.44
Refrigerator interval	7.4 $\pm$ 5.4	7.9 $\pm$ 6.3	0.80
Brain pH	6.6 $\pm$ 0.2	6.7 $\pm$ 0.2	0.44
			Fisher's exact
Gender (male/female)	8/4	13/11	0.57

**Table 2** Differentially phosphorylated peptides identified and their correspondent proteins

Biological Processes	Gene	Protein Name	Phosphopeptide Sequence	Ratio	p value (Wilcoxon)	q value
Transport	AP2A2	AP 2 complex subunit alpha 2	KGPSVTDLCTLR	0.86	0.0423	0.398
	ATP1A1	Na/K-transporting ATPase subunit alpha 1	YQLSHKPNSEPHLLVMKGAPEP	0.72	0.0059	0.124
	ATP1A3	Na/K-transporting subunit alpha-3	AOELARDGNALPPPTPEWVKFQR	0.78	0.0169	0.124
	ATP1A4	Na/K-transporting ATPase subunit alpha-4	MTVAHMFDMVTVEADTTEETGQTFK	0.75	0.0011	0.124
	ATP2B3	Plasma membrane calcium-transporting ATPase 3	LVKYTFNSLR	0.8	0.0217	0.124
	ATP2B3	Plasma membrane calcium-transporting ATPase 3	VYTFNSVNSKSLR	0.79	0.0223	0.124
	ATP2B4	Plasma membrane calcium-transporting ATPase 4	HTLVKCSGLR	0.79	0.0239	0.124
	ATP6V1G2	V type proton ATPase subunit G 2	ASGGQGLQLOAEK	0.62	0.0287	0.124
	CADPS	Calcium dependent secretion activator 1	WLFESTGVLAEDKELGR	0.75	0.0405	0.398
	GDI2	Rab GDP dissociation inhibitor beta	CKQLGDFGVK	0.71	0.0354	0.124
	RPH3A	Rabphilin 3A	IGGVGGYPAVGAREDR	0.82	0.0239	0.124
	SLC1A6	Excitatory amino acid transporter 4	LGESQQRALRFR	0.81	0.0235	0.124
	SLC25A12	Calcium binding mitochondrial carrier protein Aralar1	SKSQMSGLDFSDMLR	0.86	0.0337	0.287
	SLC3A2	4F2 cell surface antigen heavy chain	VAGSPQWVRLR	0.7	0.0366	0.287
	SYN1	Synapsin-1	WVVDNGHGFQDQSLVLTAK	0.8	0.0346	0.287
	SYN1	Synapsin-1	CSGQOTSPGALGR	0.84	0.0396	0.287
Metabolism and energy	ACO2	Acetate hydratase mitochondrial	ISREDIANLADQF	0.78	0.0390	0.287
	ATP4A	Potassium-transporting ATPase alpha chain 1	RWGDASETALKFSELTGNAMGYR	0.86	0.0340	0.287
	ATP4A	Potassium-transporting ATPase alpha chain 1	EAFQATVSSGLGR	0.72	0.0359	0.287
	ATP5A1	ATP synthase subunit alpha	QTGKSAIDINQK	0.88	0.0402	0.287
	CNP	2,3 cyclic nucleotide 3 phosphodiesterase	APFTQVSKGVPTQDSK	0.74	0.0436	0.287
	ENO2	Gamma-endase	WNQKSTEDQAEK	0.8	0.0477	0.398
	ENO3	Beta-endase	KAGNQLLKVNGKSTESQAEK	0.83	0.0252	0.124
	HK2	Hexokinase-2	GLSKETHASAPVKMLPVCATPDGTEK	0.76	0.0399	0.124
	LDHA	L-lactate dehydrogenase A chain	MATLKQDLKLLK	0.82	0.0393	0.124
	NSF	N-ethylmaleimide-sensitive fusion protein	ERLQKQGLR	0.85	0.0366	0.124
	PDHA4	Protein disulfide-isomerase A4	VQSPDYFAFSSQKNPVK	0.7	0.0144	0.124
	PGK1	Phosphoglycerate kinase 1	AAVDFKGLDNGAK	0.73	0.0396	0.124
	PRDX2	Peroxisome oxidin-2	LGCEVLGVSDQSFHLAWNPFR	0.75	0.0452	0.287
	SLC25A5	ADP/ATP translocase 2	DFLAGGVAAASQ	0.87	0.0215	0.287
	SLC25A5	ADP/ATP translocase 2	MMMSGSRGKGTDMVIGTLQDWR	0.89	0.0086	0.287
	CNDP2	Cytosolic non-specific dipeptidase	KQPCVGLR	0.81	0.0159	0.287
Protein Metabolism	CRYAB	Alpha-crystallin B chain	MDIAHPVWRPFPFPPFSR	1.19	0.0073	0.124
	CRYAB	Alpha-crystallin B chain	KQVSGFERPFR	0.79	0.0175	0.124
	HSP90AA2	Putative heat shock protein HSP 90-alpha A2	ELHNLIPKNDQTLTVDTGSLTK	0.79	0.0332	0.287
	HSP90AA2	Putative heat shock protein HSP 90-alpha A2	NLTDWEDHLAWHVSVEGLEFR	0.79	0.0130	0.287
	HSP90AB1	Heat shock protein HSP 90-beta	ETQGVYITGESK	1.4	0.0160	0.287
	HSP90AB3P	Putative heat shock protein HSP 90-beta-3	EFLQELVNASDALKIRYESTDPSK	0.76	0.0100	0.124
	HSP90AB3P	Putative heat shock protein HSP 90-beta-3	KHLENPHQMEFLR	0.75	0.0051	0.124
	HSPA12A	Heat shock 70 kDa protein 12A	LIWTFDEDFEOK	1.27	0.0027	0.124
	HSPA1L	Heat shock 70 kDa protein 1L	QTFQTFTHVQKQVQVYVEGER	1.27	0.0009	0.124
	HSPA2	Heat shock related 70 kDa protein 2	QVQFQVEVTDANGLVTAADKSSK	1.25	0.0001	0.124
	HSPA9	Stress-70 protein, mitochondrial	MKETAENGQGLK	1.28	0.0070	0.054
	HSPD1	60 kDa heat shock protein, mitochondrial	KQSPVTTPEEMQVATISANGDKKEGNIEDAMK	0.76	0.0054	0.124
	HSPD1	60 kDa heat shock protein, mitochondrial	DGVTVAKSLK	1.7	0.0021	0.124
	ACTA2	Actin, aortic smooth muscle	EAGSRGLRLK	0.8	0.0079	0.124
	ACTB2	Beta-actin-like protein 2	DLVANILSGSGMTYPGIADRMQKEITLAPSTMK	0.83	0.0058	0.124
	ACTN4	Alpha-actinin-4	MLDAEDVILARPDEK	0.86	0.0004	0.173
	ACTN4	Alpha-actinin-4	ISQEMQKLEDFR	0.85	0.0173	0.124
Cell growth and maintenance	ADD2	Beta-adducin	SLEEGTKTKEK	0.86	0.0048	0.173
	ADD2	Beta-adducin	RVLULQSPFR	0.88	0.0014	0.173
	INA	Alpha-internexin	QSLSRNSVASSAASSSLGLGLAYR	0.76	0.0010	0.173
	INA	Alpha-internexin	MALDIEAIVKLLGEETR	0.76	0.0037	0.173
	CDH13	Cadherin-13	GFQFHEHNSIVRTITLDR	0.86	0.0128	0.124
	CLTC	Clathrin heavy chain 1	RPSASAMAPSKVAKL	0.85	0.0152	0.124
	CLTC	Clathrin heavy chain 1	RPSASAMINPASK	0.85	0.0202	0.124
	CLTCL1	Clathrin heavy chain 2	EGQFKDILK	0.84	0.0257	0.124
	CLTCL1	Clathrin heavy chain 2	GRESYETIEFLPAKLR	0.81	0.0462	0.124
	CNTN1	Contactin 1	APSPSPKPPKSLR	0.85	0.0442	0.398
	DYNC11I	Cytoplasmic dynein 1 intermediate chain 1	VTVQDFLPRESQSK	0.82	0.0365	0.173
	DSP	Desmoplakin, Short-DP	ISYQAINRSMVEDQLR	0.81	0.0073	0.124
	DSC1	Desmocollin 1	SSQAFRILEDGSYTHDLLSSEK	0.78	0.0258	0.247
	EPB41L3	Band 4.1 like protein 3	HQTNGLR	0.85	0.0255	0.247
	FSCN1	Fascin	WSVHMAHPQNVNYSQVWR	0.75	0.0268	0.247
	IMMT	Mitochondrial inner membrane protein	VQKQMLKEARGLK	0.84	0.0276	0.247
	MAP1A	Microtubule-associated protein 1A	IKDLDFRRVR	0.75	0.0298	0.247
	MAP1B	Microtubule-associated protein 1B	QQDLNMLVASTVMQDESFPADKEL	0.8	0.0304	0.247
	MAP1B	Microtubule-associated protein 1B	VNHVEXPKVSEK	0.81	0.0327	0.247
	MAP1B	Microtubule-associated protein 1B	KLGGSTQDVSGSGFSK	0.85	0.0347	0.398
	MAP1B	Microtubule-associated protein 1B	TLVLEVSQSGVTSQAGHTPYQSPYQSTDEK	0.78	0.0354	0.398
	MAP2	Microtubule-associated protein 2	GLVSSPEAEVSEK	0.83	0.0369	0.247
	MAP2	Microtubule-associated protein 2	KOMQGTETEEKAPALFGLHTLVSEDMK	0.82	0.0392	0.247
	NEFL	Neurofilament light polypeptide	LAEDATNEKDALQSGREGLEETLR	0.77	0.0403	0.173
	NEFM	Neurofilament medium polypeptide	KAESPKVEAEVAEYVTLR	0.83	0.0420	0.173
	SPTAN1	Spectrin alpha chain, brain	LEKAFPRK	0.81	0.0430	0.173
	SPTBN1	Spectrin beta chain, brain 1	GRLSIEER	0.84	0.0448	0.173
	SPTBN1	Spectrin beta chain, brain 1	DLVAEAKSLQKEAEK	0.84	0.0069	0.247
	SPTBN1	Spectrin beta chain, brain 1	SONVYDSSSLSEAR	0.82	0.0467	0.398
	SPTBN1	Spectrin beta chain, brain 1	LAESDQVDEKATLK	0.86	0.0086	0.247
	SPTBN1	Spectrin beta chain, brain 1	QVSSQVWNLGSLAR	0.75	0.0206	0.173
	SPTBN2	Spectrin beta chain, brain 2	LLNKITALRGESQSR	0.87	0.0175	0.247
	SPTBN2	Spectrin beta chain, brain 2	QTRTRGAPGAPQSR	0.84	0.0162	0.247
	STX1B	Syntaxin 1B	SAKDSDEEEVHVDR	0.77	0.0151	0.173
	TAU	Full Microtubule associated protein tau	SPVVSQGLR	0.73	0.0129	0.173
	TUBA4B	Putative tubulin-like protein alpha-4B	QHTGTROPFFPEQGLK	1.22	0.0112	0.124
	TUBB1	Tubulin beta-1 chain	LVNFSVAMPSPK	1.45	0.0086	0.124
	TUBB4Q	Putative tubulin beta-4q chain	INNTFSLPSK	1.26	0.0069	0.124
	VIM	Vimentin	LGQSDVDFSLADANTFKNR	0.76	0.0065	0.124
Cell comm. and signalling	CAMK2A	Calcium calmodulin dependent protein kinase type II alpha chain	GALTLMLATRNISGKSGNKK	0.83	0.0039	0.054
	CNTNAP1	Contactin associated protein 1	YQLGSPVYQLTRPYTDGQPSHMLR	0.85	0.0187	0.247
	DNM1	Dynamin-1	QVGVNRSQKIDGK	0.76	0.0152	0.173
	DNM1	Dynamin-1	QVDMVSELSVTR	0.82	0.0369	0.173
	DNM1	Dynamin-1	NLVGSLVAVAK	0.84	0.0157	0.173
	DNM2	Dynamin-2	RREGSDQDVLTLEISGARINR	0.8	0.0192	0.173
	DNM3	Dynamin-3	RQYGVVAVQEK	0.86	0.0147	0.173
	DPYSL1	Dihydropyrimidinase-related protein 1	NVAPPQGSNVLG	0.72	0.0053	0.054
	DPYSL2	Dihydropyrimidinase-related protein 2	NLHGSFSLSGAQDNIPR	0.81	0.0018	0.054
	DPYSL2	Dihydropyrimidinase-related protein 2	KGRVAGSDADLVWDFPSK	0.77	0.0036	0.054
	FKBP2	FK506 binding protein 2	VLTVLSQLSAVATVSAEGR	0.77	0.0236	0.247
	GNAL	Guanine nucleotide binding protein G o subunit alpha	LRESLDFESWNNR	0.88	0.0408	0.247
	GNAO	Guanine nucleotide binding protein G o subunit alpha	WVGIVETFFIKNLHFR	0.75	0.0258	0.247
	PTPRD	Receptor-type tyrosine-protein phosphatase delta	LTQETGENVMELEPKR	0.82	0.0318	0.247
	PTPRZ1	Receptor-type tyrosine-protein phosphatase zeta	ITTHVKGQVWSSQSSSHLEGSK	0.73	0.0348	0.247
	RAB39B	Ras related protein Rab 39B	STRVNLFLDTNR	0.82	0.0407	0.247
Reg. nuc. acid, metab.	DDX1	ATP dependent RNA helicase DDX1	VGRARMGLASLVSEK	0.86	0.0010	0.054
	SATB2	DNA-binding protein SATB2	SGSPDVGPPPKVVAR	0.66	0.0068	0.054
Neurogenesis & Immunity	MBP	Myelin basic protein	GVDAGQTLQFQK	1.29	0.0050	0.054
	MBP	Myelin basic protein	ELNAEKLSTLQETNR	0.71	0.0033	0.054
Unknown	ACCS1	Acetyl-coenzyme A synthetase 2-like, mitochondrial	LLGSRGLSGQAPRPPGQVAPR	0.7	0.0015	0.124
	TSYPYL1	Testis specific Y encoded like protein 1	RTPLQLTIQSDQVPSDQDAHQYLR	0.72	0.0258	0.398
	CYFIP1	Cytoplasmic FMR1 interacting protein 1	LIQSVSAMMYK	0.79	0.0365	0.398
	EIF3M	Eukaryotic translation initiation factor 3 subunit M	LIQSVKRVVSHSTHR	0.82	0.0158	0.124
	OBFC1	Oligonucleotide-binding fold-containing protein 1	LGQVSEK	1.94	0.0160	0.124
	—	Putative Rab 43 like protein ENSP0000330714	SANGALAYDTNRSLSVPHWEDVR	0.66	0.0110	0.124
	SV2A	Synaptic vesicle glycoprotein 2A	ITLMMMGVWFTMSFYGLTVFWMRHLQAVDQASR	0.77	0.0060	0.124
	TT3CS	Tetraloop peptide repeat protein 35	ILQEDPTNGLARKR	0.68	0.0497	0.398

In black, proteins found with differences in expression (42).

In gray, proteins found differentially phosphorylated in more than 1 peptide

These phosphoproteins were assigned according to their biological processes in order to comprehend the

biochemical pathways associated with the differential phosphorylation signaling (Fig. 1). Seven different biological processes were represented, being “cell growth and maintenance” the most frequent class (Fig. 1a). Differentially phosphorylated proteins were also classified according to their cellular localization (Fig. 1b). Although most of them are cytoplasmic (56%), there was a significant coverage of membrane proteins (30%), which are important targets not only for protein signaling, but for potential drug targets. Phosphoproteins were also submitted to a systems biology analyses in IPKB as to be discussed ahead (Fig. 2). Considering the large-scale nature of our analyses, we performed a Western blot


**Biological Function**

Biological Function	Percentage
Cell growth/maintenance	32%
Metabolism/energy	15%
Transport	16%
Protein Metabolism	11%
Cell comm & Signalling	14%
Unknown	9%
Neurogenesis & immunity	1%
Reg. nucleic acid met.	2%

**Cellular Localization**

Cellular Localization	Percentage
Cytoplasm	56%
Plasma Membrane	30%
unknown	8%
Nucleus	5%
Extracellular Space	1%





**Fig. 3** Validation of Dynamin 1 as a candidate of differentially phosphorylated protein in the DLPFC from MDD patients and controls. *p* values were obtained by Student's *t*-test statistical analysis

validation of phosphorylated Dynamin 1, confirming the LC-MS<sup>E</sup> findings (Fig. 3).


## Discussion

Despite their obvious importance, there is still a lack about phosphoproteomic studies in psychiatric disorders [38]. It is estimated that protein phosphorylation regulates approximately one-third of the human proteins in a wide range of cellular processes [59]. Moreover, phosphoproteomic analyses could provide information about phosphorylation status, increasing the understanding about the functional aspects of the MDD. Even not using any special preparation for this purpose, we evaluate the phosphoproteomic differences in MDD compared to controls. We focused our discussion and our illustrations in the 20 proteins that showed differences in phosphorylation in at least 2 peptides, since those provide more confidence regarding differential phosphorylation. Nevertheless, the remaining 70 proteins are also important protein targets to be considered, proved by the fact that they fit in a biological and molecular context as further presented.

The identification of differential phosphorylation in subunits of clathrin (CLTC and CLTCL1), spectrin (SPTBN1 and SPTBN2) and synapsin (SYN1) as well as the identification and validation of dynamin (DNM1) (Fig. 3) reinforces the impairment of synaptic transmission in MDD [16]. As represented in Fig. 4, our phosphoproteomic findings suggest a

generalized dysregulation of the cytoskeleton signaling, which may compromise cell morphology and synaptic transmission. SPTBN1 and SPTBN2 together with other spectrin subunits like spectrin alpha chain (SPTAN1) are responsible for connecting plasma membrane to the actin cytoskeleton, playing roles in cell morphology, organelles organization and transmembrane proteins arrangement [6]. Alpha-actinin-4 (ACTN4) also belongs to the spectrin superfamily playing complementary roles to SPTBN1 and SPTBN2 and has been implicated in central nervous system (CNS) disorders such as schizophrenia and epilepsy [46]. Beta-adducin (ADD2) also plays structural roles in binding and regulating actin and spectrin filaments and contains phosphorylation sites for protein kinase C and calmodulin binding site [7]. Interestingly, Add2 KO mice presented differences in expression and phosphorylation levels of alpha- and gamma-adducin as well as impairments in synaptic plasticity, motor coordination, behavioral and learning deficits [51]. In addition, mRNA of sodium potassium transporting subunit alpha-3 (ATP1A3), calcium calmodulin dependent protein kinase type II alpha chain (CAMK2A) and vimentin (VIM) were found differentially expressed in MDD DLPFC [57].

Microtubule-associated proteins (MAPs) such as MAP1B and MAP2, which we found differentially phosphorylated in MDD DLPFC, bind to tubulin subunits for regulating microtubules assembly and stability. These are necessary for several cellular processes in brain tissue such as axonogenesis and dendritogenesis during neurodevelopment and function [1] as supported by studies in MAP1B null mice [8]. Moreover, MAP2 acts stabilizing and shaping dendrites during neuron development [13]. Interestingly, we found MAP1B less phosphorylated in MDD brain, in line with previous functional studies which suggested that a dephosphorylated state of MAP1B may trigger cytoskeletal alterations that will impair long-term potentiation leading ultimately to impaired synaptic plasticity [62]. In addition, MAP1B null adult mice presented alterations in myelin sheath diameter as well as conduction velocity of peripheral axons in the corpus callosum, which is in line with the differential phosphorylation we found for MBP in MDD DLPFC [8]. Stress-unsusceptible rats from a chronic social defeat stress model presented lower levels of Map1b mRNA in the frontal cortex and hippocampus [20]. Although we did not find significant differences in proteins expression when comparing MDD and control subjects, the reduced gene expression in the social defeat model and differential protein phosphorylation in brain tissue reinforce the role of MAP1B in the impairment of the synaptic transmission in MDD. Moreover, the inhibition of GSK-3beta by lithium leads to the loss of phosphorylated MAP-1B and thus to axonal remodeling [30], suggesting MAP1B as a potential drug target.



**Fig. 4** Integrated view of the role players of the synaptic dysfunction in MDD brains. Colored proteins were found differentially phosphorylated between MDD patients versus controls

MAP1B is also involved in growth cone and axonal activity [45] so as alpha-internexin (INA) and dihydropyrimidinase-related protein 2 (DPYSL2). INA, which is also present in dendrites, is one of the responsible proteins to maintain neuronal caliber and is involved in neuronal morphogenesis together with neurofilaments L, M (NEFL and NEFM) [11], which we also found differentially phosphorylated. DPYSL2, which acts in the regulation of axon guidance, vesicle trafficking and synaptic function, has been shown to bind and be modulated by antidepressants and neuroactive molecules [19]. INA and DPYSL2 have been found differentially expressed in schizophrenia brains [34, 35, 41]. While their phosphorylation status has not been mentioned on schizophrenia, differences in expression of these proteins have not been related to MDD so far.

Synapsin-1 (SYN1) is a neuronal membrane phosphoprotein that anchors to synaptic vesicles which is involved in axogenesis, synaptogenesis and modulation of neurotransmitter release [56] so as *N*-ethylmaleimide-sensitive fusion protein (NSF), which is a key synaptic component especially in synaptic transmission SNARE-mediated [60]. SYN1 has been implicated in psychiatric disorders and could be a target for their treatment [61]. Synaptic vesicles

reserved in the axon are converted to ready-to-release vesicles depending on SYN1 phosphorylation. When pre-synaptic membranes depolarize, there is a calcium influx into the axonal nerve, which can involve plasma membrane calcium-transporting ATPase 3 (ATP2B3) that we also found to be differentially phosphorylated. Calcium ions bind to calmodulin, and the complex calcium/calmodulin activates protein kinases that phosphorylate SYN1. In turn, SYN1 dissociates from the vesicle membrane, leading it for release [25, 54] (Fig. 4). Interestingly, SYN1 interacts with amphiphysin (AMPH) [47], which we found to be differentially expressed in MDD brains [36].

When ready-to-release synaptic vesicles reach the axonal membrane, they are mechanically involved by dynamins like DNM1, DNM2 and DNM3, which forms a spiral around the vesicle forcing their rupture at the expense of GTP hydrolysis [18] (Fig. 4). Interestingly, differences in the phosphorylation levels of clathrin heavy chain 1 and 2 (CLTC and CLTCL1) were also observed in MDD DLPFC. Clathrin complex performs a pivotal role in shaping synaptic vesicles and can be recycled after vesicle cycles also playing roles in axon guidance and organization of cellular membrane [29]. The roles of DNM1 and CLTC as well as the pivotal role of NSF can be observed in

<http://stke.sciencemag.org/content/vol2004/issue264/images/data/re19/DC2/slowtrack2.swf>. Differences in the phosphorylation levels of key proteins such as DNMT1 and CLTC can impair significantly synaptic transmission.

Although synaptic transmission is a known mechanism in MDD, revealing exactly which proteins, peptides and amino acids are differentially phosphorylated can lead to potential targets for therapeutic studies, paving way to the discovery of new drugs.

MBP, which is the major structural component of the myelin sheets in the CNS, and alpha-crystallin B (CRYAB) were identified with differential phosphorylation by two peptides, being one more phosphorylated and the other less phosphorylated. MBP gene and protein expression have been found altered consistently in schizophrenia [1, 31, 33, 42] and multiple sclerosis [55]. In addition, the differential expression of MBP in the entorhinal cortex in schizophrenia patients correlates to migrational disturbances of pre-alpha cell clusters leading to deficits in axonal myelination and disturbed connectivity during neurodevelopment [49]. CRYAB was also previously found differentially expressed in schizophrenia [41]. Therefore, the differential phosphorylation of MBP and CRYAB protein modification cannot point out a process specific for MDD, but can indicate trait processes of neuropsychiatric disorders. Considering the structural role of these proteins added to the cytoskeleton impairment described above, we here present the possible players of the impaired cytoarchitecture of MDD brain tissue. Recently, there has been found a correlation between the phosphorylation of CRYAB with apoptosis in breast cancer cells [27]. In addition, CRYAB acts as molecular chaperone [50], and the differential phosphorylation of other 3 heat shock proteins here found—putative heat shock protein HSP 90-beta-3 (HSP90AB3P), putative heat shock protein HSP 90-alpha A2 (HSP90AA2) and 60 kDa heat shock protein, mitochondrial (HSPD1)—may suggest impaired cellular environment. Interestingly, CRYAB has an autokinase activity, and posttranslational modifications decrease their role as chaperone [21].

Energy metabolism pathways have been associated intimately with MDD [3, 22, 52]. In line with these results, we observed recently that several oxidative phosphorylation enzymes were differentially expressed in MDD [36]. We found differences in the phosphorylation levels of metabolic enzymes such as aconitate hydratase (ACO2), enolase (ENO2 and ENO3), hexokinase-2 (HK2) and L-lactate dehydrogenase A (LDHA).

As for any postmortem brain tissue research, some potential limitations of our study have to be addressed. Factors such as age, gender, postmortem interval and others may confound global proteomic analyses especially in postmortem studies [23]. However, these factors are

unlikely to have had significant effects on our analyses, considering that the compared groups are matched for demographic variables and these have not shown significant differences (Table 1). In addition, no segregation of subjects has been observed using principle component analyses for medication effects (Supplementary material 1). The limited sample sizes can also be a drawback in postmortem brain tissue studies, suggesting, therefore, replication in an independent sample cohort. In addition, it is suggested validation in a larger number of samples for overcoming errors from multiple testing. Even with all potential drawbacks, we believe that the analysis of postmortem tissue from patients while studying brain disorders is indispensable as reported recently [17]. These studies have generated insights for psychiatric studies that have been useful in basic and applied research.

Interestingly, the differences in phosphorylation that we observed in MDD DLPFC brain tissue can be connected in a net of interactions and roles as described in Figs. 2 and 4. The advantage of a hypothesis-free analysis as we performed is to give the opportunity to reveal the real players of the studied disorder. Moreover, considering the signaling role of phosphorylation, which is indispensable for cellular structure, neuroplasticity and communication, the protein candidates presented here be considered therapeutic targets to be further explored in drug response and drug discovery studies.

**Acknowledgments** Authors thank sincerely all tissue donors and their families. Their comprehension and consent is essentially important to our research and to the lives of patients. We also thank the Stanley Medical Research Institute for their financial support and material donation. Special thanks to Professor E. Torrey Fuller and Dr. Maree Webster.

**Conflict of interest** None.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

## References

1. Al-Bassam J, Ozer RS, Safer D, Halpain S, Milligan RA (2002) MAP2 and tau bind longitudinally along the outer ridges of microtubule protofilaments. *J Cell Biol* 157:1187–1196
2. Ashman K, Villar EL (2009) Phosphoproteomics and cancer research. *Clin Transl Oncol* 11:356–362
3. Baxter LR Jr, Schwartz JM, Phelps ME, Mazziotta JC, Guze BH, Selin CE, Gerner RH, Sumida RM (1989) Reduction of prefrontal cortex glucose metabolism common to three types of depression. *Arch Gen Psychiatry* 46:243–250
4. Beasley CL, Pennington K, Behan A, Wait R, Dunn MJ, Cotter D (2006) Proteomic analysis of the anterior cingulate cortex in the



- major psychiatric disorders: evidence for disease-associated changes. *Proteomics* 6:3414–3425
5. Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. *J R Stat Soc* 57:289–300
  6. Bennett V, Baines AJ (2001) Spectrin and ankyrin-based pathways: metazoan inventions for integrating cells into tissues. *Physiol Rev* 81:1353–1392
  7. Bennett V, Gardner K, Steiner JP (1988) Brain adducin: a protein kinase C substrate that may mediate site-directed assembly at the spectrin-actin junction. *J Biol Chem* 263:5860–5869
  8. Bouquet C, Soares S, von Boxberg Y, Ravaille-Veron M, Propst F, Nothias F (2004) Microtubule-associated protein 1B controls directionality of growth cone migration and axonal branching in regeneration of adult dorsal root ganglia neurons. *J Neurosci* 24:7204–7213
  9. Cavallarin N, Vicario M, Negro A (2010) The role of phosphorylation in synucleinopathies: focus on Parkinson's disease. *CNS Neurol Disord Drug Targets* 9:471–481
  10. Chong PK, Lee H, Kong JW, Loh MC, Wong CH, Lim YP (2008) Phosphoproteomics, oncogenic signaling and cancer research. *Proteomics* 8:4370–4382
  11. Duprey P, Paulin D (1995) What can be learned from intermediate filament gene regulation in the mouse embryo. *Int J Dev Biol* 39:443–457
  12. Fava M, Kendler KS (2000) Major depressive disorder. *Neuron* 28:335–341
  13. Goedert M, Crowther RA, Garner CC (1991) Molecular characterization of microtubule-associated proteins tau and MAP2. *Trends Neurosci* 14:193–199
  14. Greenberg PE, Kessler RC, Birnbaum HG, Leong SA, Lowe SW, Berglund PA, Corey-Lisle PK (2003) The economic burden of depression in the United States: how did it change between 1990 and 2000? *J Clin Psychiatry* 64:1465–1475
  15. Hanger DP, Seereeram A, Noble W (2009) Mediators of tau phosphorylation in the pathogenesis of Alzheimer's disease. *Expert Rev Neurother* 9:1647–1666
  16. Harrison PJ (2002) The neuropathology of primary mood disorder. *Brain* 125:1428–1449
  17. Harrison PJ (2011) Using our brains: the findings, flaws, and future of postmortem studies of psychiatric disorders. *Biol Psychiatry* 69:102–103
  18. Henley JR, Cao H, McNiven MA (1999) Participation of dynamin in the biogenesis of cytoplasmic vesicles. *FASEB J* 13(Suppl 2):S243–S247
  19. Hensley K, Venkova K, Christov A, Gunning W, Park J (2011) Collapsin response mediator protein-2: an emerging pathologic feature and therapeutic target for neurodegeneration. *Mol Neurobiol* 43:180–191
  20. Kanarik M, Althoff A, Matrov D, Koiv K, Sharp T, Panksepp J, Harro J (2011) Brain responses to chronic social defeat stress: effects on regional oxidative metabolism as a function of a hedonic trait, and gene expression in susceptible and resilient rats. *Eur Neuropsychopharmacol* 21:92–107
  21. Kantorow M, Piatigorsky J (1994) Alpha-crystallin/small heat shock protein has autokinase activity. *Proc Natl Acad Sci USA* 91:3112–3116
  22. Kennedy SH, Evans KR, Kruger S, Mayberg HS, Meyer JH, McCann S, Arifuzzman AI, Houle S, Vaccarino FJ (2001) Changes in regional brain glucose metabolism measured with positron emission tomography after paroxetine treatment of major depression. *Am J Psychiatry* 158:899–905
  23. Kleinman JE, Law AJ, Lipska BK, Hyde TM, Ellis JK, Harrison PJ, Weinberger DR (2011) Genetic neuropathology of schizophrenia: new approaches to an old question and new uses for postmortem human brains. *Biol Psychiatry* 69:140–145
  24. Koenigs M, Grafman J (2009) The functional neuroanatomy of depression: distinct roles for ventromedial and dorsolateral prefrontal cortex. *Behav Brain Res* 201:239–243
  25. Krueger BK, Forn J, Greengard P (1977) Depolarization-induced phosphorylation of specific proteins, mediated by calcium ion influx, in rat brain synaptosomes. *J Biol Chem* 252:2764–2773
  26. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, Devon K, Dewar K, Doyle M, FitzHugh W, Funke R, Gage D, Harris K, Heaford A, Howland J, Kann L, Lehoczky J, LeVine R, McEwan P, McKernan K, Meldrum J, Mesirov JP, Miranda C, Morris W, Naylor J, Raymond C, Rosetti M, Santos R, Sheridan A, Sougnez C, Stange-Thomann N, Stojanovic N, Subramanian A, Wyman D, Rogers J, Sulston J, Ainscough R, Beck S, Bentley D, Burton J, Clee C, Carter N, Coulson A, Deadman R, Deloukas P, Dunham A, Dunham I, Durbin R, French L, Grafham D, Gregory S, Hubbard T, Humphray S, Hunt A, Jones M, Lloyd C, McMurray A, Matthews L, Mercer S, Milne S, Mullikin JC, Mungall A, Plumb R, Ross M, Shownkeen R, Sims S, Waterston RH, Wilson RK, Hillier LW, McPherson JD, Marra MA, Mardis ER, Fulton LA, Chinwalla AT, Pepin KH, Gish WR, Chissole SL, Wendt MC, Delehaunty KD, Miner TL, Delehaunty A, Kramer JB, Cook LL, Fulton RS, Johnson DL, Minx PJ, Clifton SW, Hawkins T, Branscomb E, Predki P, Richardson P, Wenning S, Slezak T, Doggett N, Cheng JF, Olsen A, Lucas S, Elkin C, Uberbacher E, Frazier M et al (2001) Initial sequencing and analysis of the human genome. *Nature* 409:860–921
  27. Launay N, Tarze A, Vicart P, Lilienbaum A (2010) Serine 59 phosphorylation of  $\alpha$ B-crystallin down-regulates its anti-apoptotic function by binding and sequestering Bcl-2 in breast cancer cells. *J Biol Chem* 285:37324–37332
  28. Li GZ, Vissers JP, Silva JC, Golick D, Gorenstein MV, Geromianos SJ (2009) Database searching and accounting of multiplexed precursor and product ion spectra from the data independent analysis of simple and complex peptide mixtures. *Proteomics* 9:1696–1719
  29. Lippincott-Schwartz J, Roberts TH, Hirschberg K (2000) Secretory protein trafficking and organelle dynamics in living cells. *Annu Rev Cell Dev Biol* 16:557–589
  30. Lucas FR, Goold RG, Gordon-Weeks PR, Salinas PC (1998) Inhibition of GSK-3 $\beta$  leading to the loss of phosphorylated MAP-1B is an early event in axonal remodelling induced by WNT-7a or lithium. *J Cell Sci* 111(Pt 10):1351–1361
  31. Martins-de-Souza D (2010) Proteome and transcriptome analysis suggests oligodendrocyte dysfunction in schizophrenia. *J Psychiatry Res* 44:149–156
  32. Martins-de-Souza D (2010) Is the word 'biomarker' being properly used by proteomics research in neuroscience? *Eur Arch Psychiatry Clin Neurosci* 260(7):561–562
  33. Martins-De-Souza D, Dias-Neto E, Schmitt A, Falkai P, Gormanns P, Maccarrone G, Turck CW, Gattaz WF (2010) Proteome analysis of schizophrenia brain tissue. *World J Biol Psychiatry* 11:110–120
  34. Martins-de-Souza D, Gattaz WF, Schmitt A, Maccarrone G, Hunyadi-Gulyas E, Eberlin MN, Souza GH, Marangoni S, Novello JC, Turck CW, Dias-Neto E (2009) Proteomic analysis of dorsolateral prefrontal cortex indicates the involvement of cytoskeleton, oligodendrocyte, energy metabolism and new potential markers in schizophrenia. *J Psychiatr Res* 43:978–986
  35. Martins-de-Souza D, Gattaz WF, Schmitt A, Novello JC, Marangoni S, Turck CW, Dias-Neto E (2009) Proteome analysis of schizophrenia patients Wernicke's area reveals an energy metabolism dysregulation. *BMC Psychiatry* 9:17
  36. Martins-de-Souza D, Guest PC, Harris LW, Vanattou-Saifoudine N, Webster MJ, Rahmoune H, Bahn S (2011) Identification of proteomic signatures associated with depression and psychotic

- depression in post-mortem brains from major depression patients. *Transl Psychiatry*. doi:10.1038/TP.2012.13
37. Martins-de-Souza D, Guest PC, Steeb H, Pietsch S, Rahmoune H, Harris LW, Bahn S (2011) Characterizing the proteome of the human dorsolateral prefrontal cortex by shotgun mass spectrometry. *Proteomics* 11:2347–2353
  38. Martins-de-Souza D, Guest PC, Vanattou-Saifoudine N, Weseling H, Rahmoune H, Bahn S (2011) The need for phosphoproteomic approaches in psychiatric research. *J Psychiatr Res* 45:1404–1406
  39. Martins-de-Souza D, Harris LW, Guest PC, Turck CW, Bahn S (2010) The role of proteomics in depression research. *Eur Arch Psychiatry Clin Neurosci* 260:499–506
  40. Martins-de-Souza D, Menezes de Oliveira B, dos Santos Farias A, Horiuchi RS, Crepaldi Domingues C, de Paula E, Marangoni S, Gattaz WF, Dias-Neto E, Camillo Novello J (2007) The use of ASB-14 in combination with CHAPS is the best for solubilization of human brain proteins for two-dimensional gel electrophoresis. *Brief Funct Genomic Proteomic* 6:70–75
  41. Martins-de-Souza D, Schmitt A, Roder R, Lebar M, Schneider-Axmann T, Falkai P, Turck CW (2010) Sex-specific proteome differences in the anterior cingulate cortex of schizophrenia. *J Psychiatr Res* 44:989–991
  42. Martins de Souza D, Dias-Neto E (2009) RNA Biomarkers in Schizophrenia. In: Turck CW (ed) *Biomarkers for psychiatric disorders*. Springer, pp 97–127
  43. Mehta D, Menke A, Binder EB (2010) Gene expression studies in major depression. *Curr Psychiatry Rep* 12:135–144
  44. Mueller M, Martens L, Apweiler R (2007) Annotating the human proteome: beyond establishing a parts list. *Biochim Biophys Acta* 1774:175–191
  45. Nozumi M, Togano T, Takahashi-Niki K, Lu J, Honda A, Taoka M, Shinkawa T, Koga H, Takeuchi K, Isobe T, Igarashi M (2009) Identification of functional marker proteins in the mammalian growth cone. *Proc Natl Acad Sci USA* 106:17211–17216
  46. Oikonomou KG, Zachou K, Dalekos GN (2011) Alpha-actinin: a multidisciplinary protein with important role in B-cell driven autoimmunity. *Autoimmun Rev* 10:389–396
  47. Onofri F, Giovedi S, Kao HT, Valtorta F, Bongiorno Borbone L, De Camilli P, Greengard P, Benfenati F (2000) Specificity of the binding of synapsin I to Src homology 3 domains. *J Biol Chem* 275:29857–29867
  48. Ozlu N, Akten B, Timm W, Haseley N, Steen H, Steen JA (2010) *Phosphoproteomics*. Wiley Interdiscip Rev Syst Biol Med 2:255–276
  49. Parlapani E, Schmitt A, Erdmann A, Bernstein HG, Breunig B, Gruber O, Petroianu G, von Wilmsdorff M, Schneider-Axmann T, Honer W, Falkai P (2009) Association between myelin basic protein expression and left entorhinal cortex pre-alpha cell layer disorganization in schizophrenia. *Brain Res* 1301:126–134
  50. Pigaga V, Quinlan RA (2006) Lenticular chaperones suppress the aggregation of the cataract-causing mutant T5P gamma C-crystallin. *Exp Cell Res* 312:51–62
  51. Porro F, Rosato-Siri M, Leone E, Costessi L, Iaconcig A, Tongiorgi E, Muro AF (2010) beta-adducin (Add2) KO mice show synaptic plasticity, motor coordination and behavioral deficits accompanied by changes in the expression and phosphorylation levels of the alpha- and gamma-adducin subunits. *Genes Brain Behav* 9:84–96
  52. Rezin GT, Amboni G, Zugno AI, Quevedo J, Streck EL (2009) Mitochondrial dysfunction and psychiatric disorders. *Neurochem Res* 34:1021–1029
  53. Rothman KJ (1990) No adjustments are needed for multiple comparisons. *Epidemiology* 1:43–46
  54. Schulman H, Greengard P (1978) Stimulation of brain membrane protein phosphorylation by calcium and an endogenous heat-stable protein. *Nature* 271:478–479
  55. Sinclair C, Mirakhur M, Kirk J, Farrell M, McQuaid S (2005) Up-regulation of osteopontin and alphaBeta-crystallin in the normal-appearing white matter of multiple sclerosis: an immunohistochemical study utilizing tissue microarrays. *Neuropathol Appl Neurobiol* 31:292–303
  56. Sudhof TC (1990) The structure of the human synapsin I gene and protein. *J Biol Chem* 265:7849–7852
  57. Tochigi M, Iwamoto K, Bundo M, Sasaki T, Kato N, Kato T (2008) Gene expression profiling of major depression and suicide in the prefrontal cortex of postmortem brains. *Neurosci Res* 60:184–191
  58. Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, Smith HO, Yandell M, Evans CA, Holt RA, Gocayne JD, Amanatides P, Ballew RM, Huseon DH, Wortman JR, Zhang Q, Kodira CD, Zheng XH, Chen L, Skupski M, Subramanian G, Thomas PD, Zhang J, Gabor Miklos GL, Nelson C, Broder S, Clark AG, Nadeau J, McKusick VA, Zinder N, Levine AJ, Roberts RJ, Simon M, Slayman C, Hunkapiller M, Bolanos R, Delcher A, Dew I, Fasulo D, Flanigan M, Florea L, Halpern A, Hannenhalli S, Kravitz S, Levy S, Mobarry C, Reinert K, Remington K, Abu-Threideh J, Beasley E, Biddick K, Bonazzi V, Brandon R, Cargill M, Chandramouliswaran I, Charlab R, Chaturvedi K, Deng Z, Di Francesco V, Dunn P, Eilbeck K, Evangelista C, Gabrielian AE, Gan W, Ge W, Gong F, Gu Z, Guan P, Heiman TJ, Higgins ME, Ji RR, Ke Z, Ketchum KA, Lai Z, Lei Y, Li Z, Li J, Liang Y, Lin X, Lu F, Merkulov GV, Milshina N, Moore HM, Naik AK, Narayan VA, Neelam B, Nusskern D, Rusch DB, Salzberg S, Shao W, Shue B, Sun J, Wang Z, Wang A, Wang X, Wang J, Wei M, Wides R, Xiao C, Yan C et al (2001) The sequence of the human genome. *Science* 291:1304–1351
  59. Walaas SI, Greengard P (1991) Protein phosphorylation and neuronal function. *Pharmacol Rev* 43:299–349
  60. Wickner W, Schekman R (2008) Membrane fusion. *Nat Struct Mol Biol* 15:658–664
  61. Yamagata Y (2003) New aspects of neurotransmitter release and exocytosis: dynamic and differential regulation of synapsin I phosphorylation by acute neuronal excitation in vivo. *J Pharmacol Sci* 93:22–29
  62. Zervas M, Opitz T, Edelmann W, Wainer B, Kucherlapati R, Stanton PK (2005) Impaired hippocampal long-term potentiation in microtubule-associated protein 1B-deficient mice. *J Neurosci Res* 82:83–92